CO6450630A2 - Preparacion de solucion que contiene anticuerpos en una alta concentracion - Google Patents

Preparacion de solucion que contiene anticuerpos en una alta concentracion

Info

Publication number
CO6450630A2
CO6450630A2 CO10091445A CO10091445A CO6450630A2 CO 6450630 A2 CO6450630 A2 CO 6450630A2 CO 10091445 A CO10091445 A CO 10091445A CO 10091445 A CO10091445 A CO 10091445A CO 6450630 A2 CO6450630 A2 CO 6450630A2
Authority
CO
Colombia
Prior art keywords
preparation
solution containing
high concentration
containing antibodies
preparation containing
Prior art date
Application number
CO10091445A
Other languages
English (en)
Inventor
Toshiyuki Morichika
Daisuke Kameoka
Yoshimi Imaeda
Terutoshi Imaeda
Oliver Boris Stauchi
Original Assignee
Chugai Pharmaceutical Co Ltd
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40824372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6450630(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd, Hoffmann La Roche filed Critical Chugai Pharmaceutical Co Ltd
Publication of CO6450630A2 publication Critical patent/CO6450630A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Como una preparación estable que contieneanticuerpos adecuada para la administración subcutáneaen donde se previenen la formación de dímeros y ladesamidación durante un almacenamiento prolongado, seprovee una preparación estable de solución que contieneun anticuerpo, la cual se caracteriza por contener argininay metionina.
CO10091445A 2007-12-27 2010-07-27 Preparacion de solucion que contiene anticuerpos en una alta concentracion CO6450630A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007336310 2007-12-27

Publications (1)

Publication Number Publication Date
CO6450630A2 true CO6450630A2 (es) 2012-05-31

Family

ID=40824372

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10091445A CO6450630A2 (es) 2007-12-27 2010-07-27 Preparacion de solucion que contiene anticuerpos en una alta concentracion

Country Status (31)

Country Link
US (9) US8568720B2 (es)
EP (1) EP2238985B2 (es)
JP (7) JP4937358B2 (es)
KR (1) KR101083616B1 (es)
CN (2) CN106075434B (es)
AR (2) AR069969A1 (es)
AU (1) AU2008344292B2 (es)
BR (1) BRPI0818903B8 (es)
CA (1) CA2708627C (es)
CL (1) CL2008003910A1 (es)
CO (1) CO6450630A2 (es)
CR (1) CR11594A (es)
CY (1) CY1113616T1 (es)
DK (1) DK2238985T4 (es)
EC (1) ECSP10010370A (es)
ES (1) ES2389881T5 (es)
HR (1) HRP20120903T4 (es)
IL (2) IL206548A (es)
MA (1) MA31934B1 (es)
MX (1) MX2010004399A (es)
MY (1) MY159450A (es)
NZ (1) NZ586378A (es)
PE (1) PE20091174A1 (es)
PL (1) PL2238985T5 (es)
PT (1) PT2238985E (es)
RU (2) RU2497544C2 (es)
SG (1) SG2013049325A (es)
SI (1) SI2238985T2 (es)
TW (1) TWI375566B (es)
UA (1) UA104134C2 (es)
WO (1) WO2009084659A1 (es)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE547119T1 (de) 1997-03-21 2012-03-15 Chugai Pharmaceutical Co Ltd Präventives oder therapeutisches mittel mit einem il-6-antagonisten als wirkstoff für durch sensibilisierte t-zellen vermittelte erkrankungen
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
SI1475101T1 (sl) 2002-02-14 2011-03-31 Chugai Pharmaceutical Co Ltd Farmacevtski proizvodi iz raztopine, ki vsebuje protitelo
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP3269738A1 (en) 2004-03-24 2018-01-17 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleukin-6 receptor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1870459B1 (en) 2005-03-31 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
EP1977763A4 (en) * 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd STABILIZER PREPARATION CONTAINING ANTIBODIES
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
HUE029635T2 (en) 2007-09-26 2017-03-28 Chugai Pharmaceutical Co Ltd A method for modifying an isoelectric point of an antibody by amino acid substitution in CDR
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
SI3202785T1 (sl) 2009-10-26 2024-08-30 F. Hoffmann-La Roche Ag Postopek za proizvodnjo glikoziliranega imunoglobulina
RU2609658C2 (ru) * 2009-12-21 2017-02-02 Дженентек, Инк. Состав, содержащий антитело
AU2013202276B2 (en) * 2009-12-21 2016-03-24 Genentech, Inc. Antibody formulation
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
SG189220A1 (en) * 2010-10-06 2013-05-31 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
WO2012064627A2 (en) 2010-11-08 2012-05-18 Genentech, Inc. Subcutaneously administered anti-il-6 receptor antibody
RU2620071C2 (ru) 2010-11-17 2017-05-22 Чугаи Сеияку Кабушики Каиша Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
WO2012101251A1 (en) 2011-01-28 2012-08-02 Sanofi Human antibodies to pcsk9 for use in methods of treatment based on particular dosage regimens
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
KR20140066124A (ko) * 2011-04-07 2014-05-30 글락소스미스클라인 엘엘씨 점도가 감소된 제제
EA201391488A1 (ru) * 2011-04-07 2014-01-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Композиции со сниженной вязкостью
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US9574005B2 (en) 2011-07-19 2017-02-21 Chugai Seiyaku Kabushiki Kaisha Stable Protein-containing preparation containing argininamide or analogous compound thereof
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
CN103889555B (zh) 2011-09-01 2018-10-26 中外制药株式会社 通过超滤制备包含高度浓缩的抗体的组合物的方法
KR102196009B1 (ko) 2011-10-25 2021-01-04 프로테나 바이오사이언시즈 리미티드 항체 제형 및 방법
EP2771033A4 (en) 2011-10-28 2016-02-17 Integritybio Inc PROTEIN FORMULATIONS CONTAINING AMINO ACIDS
EP3912639A1 (en) 2012-03-07 2021-11-24 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
RU2711089C2 (ru) 2012-05-18 2020-01-15 Дженентек, Инк. Высококонцентрированные составы моноклональных антител
WO2014010586A1 (ja) * 2012-07-10 2014-01-16 武田薬品工業株式会社 注射用製剤
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
EA201791717A1 (ru) 2012-09-07 2018-03-30 Кохерус Байосайенсис, Инк. Стабильные водные составы адалимумаба
AU2013326932B2 (en) 2012-10-04 2019-06-06 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
BR112015008186A2 (pt) * 2012-10-25 2017-09-19 Medimmune Llc formulação de um anticorpo estável e de baixa viscosidade
RU2674996C2 (ru) 2013-07-04 2018-12-14 Ф. Хоффманн-Ля Рош Аг Иммуноферментный анализ с подавлением интерференции для определения антител к лекарствам в образцах сыворотки
RU2675824C2 (ru) 2013-09-11 2018-12-25 Игл Байолоджикс, Инк. Жидкие белковые составы, содержащие ионные жидкости
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
TWI694836B (zh) * 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
MX2017003121A (es) * 2014-09-15 2017-08-02 Genentech Inc Formulaciones de anticuerpos.
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
KR102497368B1 (ko) 2014-10-01 2023-02-10 이글 바이올로직스 인코포레이티드 점도-저하제를 함유하는 폴리삭카라이드 및 핵산 제형
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
EP3224341B1 (en) 2014-11-25 2021-05-19 Corning Incorporated Cell culture media extending materials and methods
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2016109822A1 (en) * 2014-12-31 2016-07-07 Novelmed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies
US10485870B2 (en) 2015-02-11 2019-11-26 Gmax Biopharm Llc. Stable pharmaceutical solution formulation of GLP-1R antibody fusion protein
AR103726A1 (es) 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
CN107922507B (zh) 2015-08-18 2022-04-05 瑞泽恩制药公司 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者
WO2017057644A1 (ja) * 2015-09-30 2017-04-06 持田製薬株式会社 高濃度抗体含有液体製剤
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
CA3008779A1 (en) * 2015-12-18 2017-06-22 Astellas Pharma Inc. Pharmaceutical composition comprising anti-human tslp receptor antibody
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION
WO2017147169A1 (en) 2016-02-22 2017-08-31 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
CA3015347A1 (en) * 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
MA44780A (fr) * 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
TWI826351B (zh) * 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 Ｒ抗體,其藥物組合物及其應用
KR20240073999A (ko) * 2016-07-05 2024-05-27 사노피 항체 제형
CN109661241A (zh) 2016-09-06 2019-04-19 中外制药株式会社 使用识别凝血因子ix和/或活化凝血因子ix以及凝血因子x和/或活化凝血因子x的双特异性抗体的方法
CN109862880A (zh) * 2016-09-27 2019-06-07 德国费森尤斯卡比有限公司 液体药物组合物
ES2882181T3 (es) 2016-10-31 2021-12-01 Fresenius Kabi Deutschland Gmbh Composición farmacéutica líquida
PE20191436A1 (es) 2016-12-23 2019-10-14 Serum Institute Of India Pvt Ltd Metodos mejorados para estimular la productividad de anticuerpos en el cultivo de celulas de mamiferos y reducir la agregacion durante los procesos de formulacion post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos
KR20200012823A (ko) 2017-02-01 2020-02-05 예일 유니버시티 이뇨제 내성의 치료
GB201703063D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
TWI761453B (zh) * 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3596175A4 (en) 2017-03-17 2021-01-13 The Ohio State Innovation Foundation NANOPARTICLE FOR THE DELIVERY OF CHEMOPREVENTIVE AGENTS
JPWO2018179138A1 (ja) * 2017-03-29 2020-02-06 持田製薬株式会社 抗体含有液体製剤
EP3603669B1 (en) 2017-03-31 2024-06-19 Meiji Seika Pharma Co., Ltd. Aqueous formulation, aqueous formulation in injector, antibody protein disaggregating agent, and antibody protein disaggregation method
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
EP3672632A1 (en) * 2017-08-22 2020-07-01 Biogen MA Inc. Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies
JOP20200041A1 (ar) 2017-08-22 2020-02-20 Biogen Ma Inc تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي
UA128389C2 (uk) 2017-09-29 2024-07-03 Чугаі Сейяку Кабусікі Кайся Мультиспецифічна антигензв'язувальна молекула, яка має активність заміщувати кофакторну функцію фактора коагуляції крові viii (fviii), та фармацевтичний склад, який містить згадану молекулу як активний інгредієнт
EP3735421A4 (en) 2018-01-05 2021-09-22 Corvidia Therapeutics, Inc. METHOD OF TREATMENT OF IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNSUPPRESSION
CA3099551A1 (en) 2018-05-10 2019-11-14 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
CA3111784A1 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Methods and compositions for the treatment of disease with immune stimulatory conjugates
MX2021010420A (es) * 2019-03-11 2021-11-12 Biogen Ma Inc Composiciones farmacéuticas que contienen anticuerpos antilingo-1.
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
US12024553B2 (en) * 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies
KR102169901B1 (ko) * 2019-05-17 2020-10-26 연세대학교 산학협력단 Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
CN114341185A (zh) 2019-06-19 2022-04-12 希沃尔拜克治疗公司 抗间皮素抗体及其免疫缀合物
CN112618482A (zh) * 2019-09-24 2021-04-09 江苏恒瑞医药股份有限公司 新型蛋白制剂
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
JP2023518814A (ja) 2020-03-23 2023-05-08 ジェネンテック， インコーポレイテッド Ｃｏｖｉｄ－１９肺炎における、ｉｌ－６アンタゴニストに対する応答を予測するためのバイオマーカー
JP2023518815A (ja) 2020-03-23 2023-05-08 ジェネンテック， インコーポレイテッド Ｉｌ６アンタゴニストによるｃｏｖｉｄ－１９肺炎を含む肺炎の治療方法
WO2021194860A1 (en) 2020-03-23 2021-09-30 Genentech, Inc. Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
CN115776879A (zh) * 2020-06-29 2023-03-10 韩兀生物制药股份有限公司 抗fcrn抗体制剂
EP4175673A1 (en) 2020-07-01 2023-05-10 ARS Pharmaceuticals Inc. Anti-asgr1 antibody conjugates and uses thereof
KR20220028972A (ko) * 2020-08-31 2022-03-08 (주)셀트리온 안정한 약제학적 제제
CN116685351A (zh) 2020-09-17 2023-09-01 基因泰克公司 Empacta的结果：一项用于评估托珠单抗在患有covid-19肺炎的住院患者中的功效和安全性的随机、双盲、安慰剂对照、多中心研究
US20230399402A1 (en) * 2020-11-03 2023-12-14 La Jolla Institute For Immunology Hla class ii-restricted tcrs against the kras g12>v activating mutation
KR20230130561A (ko) * 2022-03-02 2023-09-12 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Fviii 모방 이중특이적 항체를 2주마다 1회 투여하는 방법
KR20230130560A (ko) * 2022-03-02 2023-09-12 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Fviii 모방 이중특이적 항체의 주 1회 투여 방법
KR20230130558A (ko) * 2022-03-02 2023-09-12 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Fviii 모방 이중특이적 항체의 월 1회 투여 방법
WO2024090488A1 (ja) * 2022-10-26 2024-05-02 日本メジフィジックス株式会社 放射性医薬組成物
WO2024158880A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55106216A (en) 1979-02-09 1980-08-14 Hitachi Chem Co Ltd Preparation of amino resin
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPS63453A (ja) 1986-06-20 1988-01-05 Tohoku Metal Ind Ltd 耐酸化性永久磁石材料とその製造方法
CA1341152C (en) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
US6428979B1 (en) 1988-01-22 2002-08-06 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
DK0628639T3 (da) 1991-04-25 2000-01-24 Chugai Pharmaceutical Co Ltd Rekonstitueret humant antistof mod human interleukin-6-receptor
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methoden zur Herstellung humanisierter Antikörper
ES2313867T3 (es) 1991-12-02 2009-03-16 Medical Research Council Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU701342B2 (en) 1994-07-13 1999-01-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
JP3630453B2 (ja) 1994-09-30 2005-03-16 中外製薬株式会社 Ｉｌ−６レセプター抗体を有効成分とする未熟型骨髄腫細胞治療剤
CN100350973C (zh) 1994-10-21 2007-11-28 岸本忠三 用于治疗il－6产生所致疾病的药物组合物
JP4079461B2 (ja) 1994-12-29 2008-04-23 中外製薬株式会社 Ｉｌ−６アンタゴニストを含んでなる抗腫瘍剤の作用増強剤
CA2211578C (en) 1995-02-13 2010-09-21 Chugai Seiyaku Kabushiki Kaisha Muscle protein proteolysis inhibiting agent containing il-6 receptor antibody
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
PT923941E (pt) 1996-06-27 2006-09-29 Chugai Pharmaceutical Co Ltd Medicamentos para mieloma a serem utilizados com agentes antitumorais de mostarda nitrogenada
HUP9904177A3 (en) 1996-09-26 2001-10-29 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
ATE547119T1 (de) 1997-03-21 2012-03-15 Chugai Pharmaceutical Co Ltd Präventives oder therapeutisches mittel mit einem il-6-antagonisten als wirkstoff für durch sensibilisierte t-zellen vermittelte erkrankungen
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
US6723319B1 (en) 1998-03-17 2004-04-20 Chugai Seiyaku Kabushiki Kaisha Method of treating inflammatory intestinal diseases containing as the ingredient IL-6 receptors antibodies
ATE512225T1 (de) 1998-04-03 2011-06-15 Chugai Pharmaceutical Co Ltd Humanisierter antikörper gegen den menschlichen gewebefaktor (tf) und verfahren für die konstruktion eines solchen humanisierten antikörpers.
US6537782B1 (en) 1998-06-01 2003-03-25 Chugai Seiyaku Kabushiki Kaisha Media for culturing animal cells and process for producing protein by using the same
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
DE69934698T2 (de) 1998-08-24 2007-10-04 Chugai Seiyaku K.K. Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
JP2007204498A (ja) 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
IL146954A0 (en) * 1999-06-25 2002-08-14 Genentech Inc HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
BRPI0017437B8 (pt) 1999-10-04 2021-05-25 Chiron Corp composição farmacêutica estabilizada contendo polipeptídeo il-2, método para aumentar estabilidade de interleucina-2 em uma composição farmacêutica, e uma forma seca da composição
JP4683810B2 (ja) 2000-02-29 2011-05-18 中外製薬株式会社 長期安定化製剤
TWI242043B (en) 2000-03-10 2005-10-21 Chugai Pharmaceutical Co Ltd Polypeptide inducing apoptosis
AU2001278716A1 (en) 2000-08-10 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Method of inhibiting antibody-containing solution from coagulating or becoming turbid
EP1314437B1 (en) * 2000-08-11 2014-06-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
AU8260701A (en) 2000-09-01 2002-03-13 Chugai Pharmaceutical Co Ltd Solution preparations stabilized over long time
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE60139944D1 (de) * 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
AU1091702A (en) 2000-10-20 2002-04-29 Chugai Pharmaceutical Co Ltd Degraded tpo agonist antibody
DK1334731T3 (da) 2000-10-25 2008-05-26 Chugai Pharmaceutical Co Ltd Forebyggende eller terapeutisk middel mod psoriasis omfattende anti-IL-6-receptorantistof som aktiv bestanddel
AU2000279625A1 (en) 2000-10-27 2002-05-15 Chugai Seiyaku Kabushiki Kaisha Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
WO2002036164A1 (fr) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent abaissant le taux sanguin de vegf contenant un antagoniste de il-6 en tant que principe actif
EP3088412B1 (en) 2001-03-09 2021-05-05 Chugai Seiyaku Kabushiki Kaisha Protein purification method
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
JP5290489B2 (ja) 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
BRPI0214168B8 (pt) * 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
US20030138416A1 (en) * 2001-12-03 2003-07-24 Jesper Lau Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
SI1475101T1 (sl) 2002-02-14 2011-03-31 Chugai Pharmaceutical Co Ltd Farmacevtski proizvodi iz raztopine, ki vsebuje protitelo
ATE402716T1 (de) * 2002-02-27 2008-08-15 Immunex Corp Stabilisierte tnfr-fc formulierung mit arginin
JP3822137B2 (ja) 2002-05-20 2006-09-13 中外製薬株式会社 動物細胞培養用培地の添加剤およびそれを用いたタンパク質の製造方法
EP1545578A4 (en) 2002-08-28 2010-07-07 Immunex Corp COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASES
CN100522989C (zh) 2002-09-11 2009-08-05 中外制药株式会社 纯化蛋白质的方法
DE10255508A1 (de) 2002-11-27 2004-06-17 Forschungszentrum Jülich GmbH Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
MXPA05008713A (es) 2003-02-24 2005-09-20 Chugai Pharmaceutical Co Ltd Agente terapeutico para dano de medula espinal que comprende antagonista de interluceina-6.
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
TW200510532A (en) 2003-07-15 2005-03-16 Chugai Pharmaceutical Co Ltd IgM production by transformed cell and method of quantifying the same
SI1690550T1 (sl) 2003-10-17 2012-12-31 Chugai Seiyaku Kabushiki Kaisha Terapevtska sredstva za mezoteliom
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
JPWO2005063291A1 (ja) 2003-12-25 2007-07-19 麒麟麦酒株式会社 抗体を含有する安定な水性医薬製剤
CN1953768B (zh) 2004-02-12 2010-10-13 默克专利有限公司 抗-egfr抗体的高浓缩液体制剂
WO2005089503A2 (en) * 2004-03-19 2005-09-29 Progenics Pharmaceuticals, Inc. Cd4-igg2 formulations
EP3269738A1 (en) 2004-03-24 2018-01-17 Chugai Seiyaku Kabushiki Kaisha Subtypes of humanized antibody against interleukin-6 receptor
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
CN101014617B (zh) * 2004-08-17 2011-03-30 瑞泽恩制药公司 Il-1拮抗剂制剂
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1835022B1 (en) 2005-01-05 2015-02-11 Chugai Seiyaku Kabushiki Kaisha Cell culture method and utilization of the same
SV2008002394A (es) 2005-01-28 2008-02-08 Wyeth Corp Formulaciones liquidas estabilizadas de polipeptido ref. ahn- 072sv
EA014513B1 (ru) 2005-08-03 2010-12-30 Иммьюноджен, Инк. Композиция иммуноконъюгата
CA2625773C (en) 2005-10-14 2015-05-12 Fukuoka University Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
KR101239051B1 (ko) 2005-10-21 2013-03-04 추가이 세이야쿠 가부시키가이샤 심장질환 치료제
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
EP1967209B1 (en) 2005-11-25 2012-06-06 Keio University Therapeutic agent for prostate cancer
EP1977763A4 (en) * 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd STABILIZER PREPARATION CONTAINING ANTIBODIES
AU2007208678B2 (en) 2006-01-27 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for diseases involving choroidal neovascularization
JP2009525986A (ja) * 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
BRPI0708677A2 (pt) 2006-03-09 2011-06-21 Hoffmann La Roche ensaio de anticorpo antifármaco
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
US9260516B2 (en) 2006-04-07 2016-02-16 Osaka University Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
MX2008013508A (es) 2006-04-21 2008-10-31 Novartis Ag Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40.
WO2008016134A1 (fr) 2006-08-04 2008-02-07 Norihiro Nishimoto PROCÉDÉ POUR PRÉDIRE LE PRONOSTIC DES PATIENTS ATTEINTS DE POLYARTHRITE rhumatoïde
JP2010095445A (ja) 2006-12-27 2010-04-30 Tokyo Medical & Dental Univ Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤
JP5419709B2 (ja) 2007-01-09 2014-02-19 ワイス・エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
EP2123302B1 (en) 2007-01-23 2015-12-09 Shinshu University Il-6 inhibitors to treat chronic rejection
JP5424330B2 (ja) 2007-07-26 2014-02-26 国立大学法人大阪大学 インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
CN101939425B (zh) 2007-09-26 2014-05-14 中外制药株式会社 抗il-6受体抗体
BRPI0817482B8 (pt) 2007-10-02 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
JP2009092508A (ja) 2007-10-09 2009-04-30 Norihiro Nishimoto リウマチ治療剤の効果の予測方法
WO2009077127A1 (en) 2007-12-15 2009-06-25 F. Hoffmann-La Roche Ag Distinguishing assay
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
TW201503898A (zh) 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd 神經浸潤抑制劑
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
TWI523661B (zh) 2009-07-31 2016-03-01 Shin Maeda Anti-IL-6 receptor antibody in the manufacture of inhibitors of metastatic inhibition of lung cancer metastasis to the liver
SI3202785T1 (sl) 2009-10-26 2024-08-30 F. Hoffmann-La Roche Ag Postopek za proizvodnjo glikoziliranega imunoglobulina
TWI609698B (zh) † 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
WO2011128096A1 (en) 2010-04-16 2011-10-20 Roche Diagnostics Gmbh Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
US20130149302A1 (en) 2010-05-28 2013-06-13 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for pancreatic cancer
DK2578231T3 (da) 2010-05-28 2022-12-12 Chugai Pharmaceutical Co Ltd Antitumor-t-celle-reaktionsforstærker
CA2801107A1 (en) 2010-06-07 2011-12-15 F. Hoffman-La Roche Ag Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
WO2012064627A2 (en) 2010-11-08 2012-05-18 Genentech, Inc. Subcutaneously administered anti-il-6 receptor antibody
CN103889555B (zh) 2011-09-01 2018-10-26 中外制药株式会社 通过超滤制备包含高度浓缩的抗体的组合物的方法
RU2674996C2 (ru) 2013-07-04 2018-12-14 Ф. Хоффманн-Ля Рош Аг Иммуноферментный анализ с подавлением интерференции для определения антител к лекарствам в образцах сыворотки
US10349940B2 (en) 2015-08-24 2019-07-16 Ethicon Llc Surgical stapler buttress applicator with state indicator
CN109862880A (zh) 2016-09-27 2019-06-07 德国费森尤斯卡比有限公司 液体药物组合物
ES2882181T3 (es) 2016-10-31 2021-12-01 Fresenius Kabi Deutschland Gmbh Composición farmacéutica líquida
MX2020005630A (es) 2017-11-30 2020-08-20 Bio Thera Solutions Ltd Formulacion liquida de anticuerpos humanizados para el tratamiento de enfermedades relacionadas con il-6.

Also Published As

Publication number Publication date
ECSP10010370A (es) 2010-08-31
CL2008003910A1 (es) 2009-07-03
IL238896A (en) 2016-06-30
AU2008344292B2 (en) 2012-11-08
HRP20120903T1 (hr) 2012-12-31
BRPI0818903B1 (pt) 2021-04-06
PL2238985T3 (pl) 2013-03-29
US20240317869A1 (en) 2024-09-26
EP2238985B9 (en) 2012-12-26
RU2010131179A (ru) 2012-02-10
JP2023055780A (ja) 2023-04-18
JP6259436B2 (ja) 2018-01-10
RU2701181C2 (ru) 2019-09-25
SG2013049325A (en) 2015-01-29
BRPI0818903A2 (pt) 2015-05-12
JP2018076334A (ja) 2018-05-17
CA2708627C (en) 2016-10-11
EP2238985B2 (en) 2022-07-27
PL2238985T5 (pl) 2023-07-17
US11584798B2 (en) 2023-02-21
US20200079857A1 (en) 2020-03-12
AR122312A2 (es) 2022-08-31
AR069969A1 (es) 2010-03-03
BRPI0818903B8 (pt) 2021-05-25
JP2021155453A (ja) 2021-10-07
US20160090419A1 (en) 2016-03-31
IL238896A0 (en) 2015-07-30
KR20100095474A (ko) 2010-08-30
CY1113616T1 (el) 2016-06-22
ES2389881T3 (es) 2012-11-02
EP2238985B1 (en) 2012-08-29
MX2010004399A (es) 2010-08-16
JP2016065079A (ja) 2016-04-28
MA31934B1 (fr) 2010-12-01
CA2708627A1 (en) 2009-07-09
PE20091174A1 (es) 2009-08-03
CN106075434B (zh) 2020-02-14
US20230167183A1 (en) 2023-06-01
US20210246216A1 (en) 2021-08-12
SI2238985T1 (sl) 2012-12-31
CN101883588A (zh) 2010-11-10
ES2389881T9 (es) 2013-01-15
SI2238985T2 (sl) 2022-09-30
IL206548A (en) 2015-06-30
CR11594A (es) 2010-10-05
NZ586378A (en) 2012-06-29
EP2238985A4 (en) 2011-01-12
UA104134C2 (ru) 2014-01-10
JP5906067B2 (ja) 2016-04-20
JP2019206559A (ja) 2019-12-05
AU2008344292A1 (en) 2009-07-09
IL206548A0 (en) 2010-12-30
US11008394B2 (en) 2021-05-18
US20140005367A1 (en) 2014-01-02
MY159450A (en) 2017-01-13
TW200942259A (en) 2009-10-16
US8568720B2 (en) 2013-10-29
PT2238985E (pt) 2012-11-28
JP2012072170A (ja) 2012-04-12
RU2497544C2 (ru) 2013-11-10
KR101083616B1 (ko) 2011-11-16
RU2019128863A (ru) 2021-03-16
HRP20120903T4 (hr) 2022-09-02
US20100285011A1 (en) 2010-11-11
TWI375566B (en) 2012-11-01
CN101883588B (zh) 2017-05-10
US11767363B2 (en) 2023-09-26
US20220281988A1 (en) 2022-09-08
WO2009084659A1 (ja) 2009-07-09
US11359026B2 (en) 2022-06-14
RU2013137740A (ru) 2015-02-20
ES2389881T5 (es) 2022-10-07
JP6567024B2 (ja) 2019-08-28
DK2238985T4 (da) 2022-10-17
US20230340134A1 (en) 2023-10-26
JPWO2009084659A1 (ja) 2011-05-19
EP2238985A1 (en) 2010-10-13
JP7256234B2 (ja) 2023-04-11
DK2238985T3 (da) 2012-11-19
JP4937358B2 (ja) 2012-05-23
CN106075434A (zh) 2016-11-09

Similar Documents

Publication Publication Date Title
CO6450630A2 (es) Preparacion de solucion que contiene anticuerpos en una alta concentracion
BRPI1012141A2 (pt) conjugado de sirna e método de preparação do mesmo
ECSP099642A (es) Formulaciones estables de anticuerpo
NZ629204A (en) Anti-vla1 (cd49a) antibody pharmaceutical compositions
WO2011109365A3 (en) Concentrated protein formulations and uses thereof
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
ECSP12012298A (es) Formulaciones de insulina de acción prolongada
ECSP12011631A (es) Composición de insulina de acción prolongada
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
EP3778917A3 (en) Multispecific antibodies, antibody analogs, compositions, and methods
DK1725660T3 (da) Ekspressionskassetter med multiple promotorer til samtidig afgivelse af RNAi-midler
BR112014010818A2 (pt) método para preparar complexo de polipeptídeo fisiologicamente ativo
CL2013003111A1 (es) Metodo para la preparacion de una composicion farmaceutica que contiene un transportador de oxigeno purificado y termicamente estable, que contiene el transportador de oxigeno hemoglobina, donde la hemoglobina incluye a hemoglobina polimerica entrecruzada.
CY1113999T1 (el) Σταθερο ετοιμο προς χρηση ενεσιμο σκευασμα παρακεταμολης
BR112014017163A8 (pt) composição de colírio
RS53408B (en) PHARMACEUTICAL COMPOSITION OF IBUPROFEN FOR INJECTION
EA201270745A1 (ru) Улучшенный стабильный водный состав (e)-4-карбоксистирил-4-хлорбензилсульфона
PA8789601A1 (es) Proceso para la preparación de trifluoralquil-fenil sulfonamidas y de sulfonamidas heterocíclicas
ES2552521T3 (es) Infusión intravenosa de ibuprofeno
EA201690401A1 (ru) Способы введения соединений, являющихся агонистами тромбопоэтина
RU2012154781A (ru) Способ исследования состояния белоксинтезирующей функции печени
RU2013151036A (ru) Интраоперационный способ купирования спазма коронарных артерий в кардиохирургии
UA69392U (ru) Способ создания биологической модели отравления лабораторных животных цезием
RU2009126306A (ru) Способ получения эритроцитарного антигенного диагностикума

Legal Events

Date Code Title Description
FC Application refused